2-isobutyryl-3-methylthiophene

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-isobutyryl-3-methylthiophene
• 英文别名: 2-Methyl-1-(3-methyl-thiophen-2-yl)-propan-1-one；2-methyl-1-(3-methylthiophen-2-yl)propan-1-one
• 化学式: C₉H₁₂OS
• 分子量: 168.26
• InChiKey: XIMNIGHGEMYQHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-甲基噻吩 、 异丁酸酐 在 Yb[C(SO₂(C₄H₉)3)3]3 作用下， 以 various solvent(s) 为溶剂， 反应 20.0h， 生成 2-isobutyryl-3-methylthiophene 、 2-isobutyryl-4-methylthiophene
  参考文献：
  名称：

  用于真正催化 Friedel-Crafts 酰化反应的高活性镱 (III) 甲基化物配合物

  摘要：

  使用镱 (III) 三[三（九氟丁烷磺酰基）甲基化物] 对苯甲醚与乙酸酐的 Friedel-Crafts 酰化进行了研究，研究了催化剂负载。从掺杂实验和动力学数据的检查中可以明显看出由于该产物产生的强抑制作用。这种理解允许将催化剂负载量减少到 0.1 mol%，以便在合适的温度和压力范围内进行有效的酰化。

  DOI：

  10.1055/s-2002-34231

文献信息

• [EN] OXIMYL MACROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS MACROCYCLIQUES D'OXIMYLE
  申请人：ENANTA PHARM INC

  公开号：WO2009073713A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ( i ) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及式I化合物，或其药用可接受的盐、酯或前药：(i)抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒(HCV) NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的对象服用。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS
  申请人：Pulici Maurizio

  公开号：US20110118278A1

  公开（公告）日：2011-05-19

  There are provided bicyclic carbonylamino-pyrazoles of formula (I), wherein the variables are as specified in the claims, for use as medicament, in particular for the treatment of diseases due to the malfunctioning of protein kinases (PKs), such as cancer, pharmaceutical compositions comprising such carbamoyl derivatives, and their use as prodrugs of therapeutically active agents. Method of treatment and some new bicyclic carbonylamino-pyrazoles are also object of the present invention.

  本发明提供了式(I)的双环羰基氨基吡唑化合物，其中变量如权利要求中所述，用作药物，特别是用于治疗由蛋白激酶（PKs）功能失调引起的疾病，如癌症，包含此类羰酰基衍生物的制药组合物，并将其用作治疗活性剂的前药。本发明还涉及治疗方法和一些新的双环羰基氨基吡唑化合物。
• PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Wagaw Seble

  公开号：US20090156800A1

  公开（公告）日：2009-06-18

  The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds.
• OXIMYL MACROCYCLIC DERIVATIVES
  申请人：Sun Ying

  公开号：US20090191153A1

  公开（公告）日：2009-07-30

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• US8193346B2
  申请人：——

  公开号：US8193346B2

  公开（公告）日：2012-06-05